Loading...
EHA congress2020-09-15T14:29:58+01:00

EHA 2020 – virtual

Preface – EHA 2020

Preface – EHA 2020 Constantine Tam, MB, BS (Hons), MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne Melbourne, Australia Dear Colleagues, Due to the circumstances brought about by the COVID-19 pandemic, the 25th European Hematology Association (EHA) Annual Congress had to take place as a virtual edition, although this raised new possibilities such as a 10-day program.

Waldenström’s macroglobulinemia: BTK inhibition and other treatments

Waldenström’s macroglobulinemia: BTK inhibition and other treatments Within the group of non-Hodgkin lymphoma, Waldenström’s macroglobulinemia (WM), an indolent B-cell lymphoplasmacytic lymphoma, accounts for approximately 2 % of cases [1]. This disease is deemed incurable and typically involves infiltration of tissues such as bone marrow, lymph nodes and/or spleen with clonal lymphoplasmacytic cells, as well as serum monoclonal paraprotein production.

Optimizing timing, efficacy and tolerability in chronic lymphocytic leukemia

Optimizing timing, efficacy and tolerability in chronic lymphocytic leukemia Acalabrutinib vs. ibrutinib In both treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), inhibition of Bruton’s tyrosine kinase (BTK) represents a treatment standard as it has improved clinical outcomes [1]. Compared to the first-generation agent ibrutinib, the second-generation, highly selective BTK inhibitor acalabrutinib shows minimal off-target kinase inhibition [2], thus potentially offering an optimized safety profile.

Changing paradigms in the management of mantle cell lymphoma

Changing paradigms in the management of mantle cell lymphoma Mantle cell lymphoma (MCL) is a rare, heterogenous and generally aggressive subtype of B-cell non-Hodgkin lymphoma that remains incurable in the majority of cases. Median survival in non-trial patients has been estimated at 3 to 5 years [1]. First-line therapy usually consists of chemoimmunotherapy, while both immunochemotherapy and targeted agents are recommended in relapsed disease [2]. However, trials increasingly challenge the role of chemotherapy against the novel agents, especially in the front-line setting.

Targeted approaches in various B-cell malignancies

Targeted approaches in various B-cell malignancies Zanubrutinib plus rituximab BTK inhibitors are active in many B-cell malignancies such as mantle cell lymphoma, CLL and Waldenström’s macro­globulinemia, but also in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and marginal zone lymphoma (MZL). Zanubrutinib is currently being assessed in pivotal phase II and III studies in all of these indications. An ongoing, single-arm, multicenter, phase II study is evaluating zanubrutinib plus rituximab in patients with relapsed/refractory non-germinal center B-cell-like (non-GCB) DLBCL (n = 20), FL (n = 16) and MZL (n = 5).

Cold agglutinin disease: on the road to new insights and potential treatment options

Cold agglutinin disease: on the road to new insights and potential treatment options Cold agglutinin disease (CAD) is a rare type of autoimmune hemolytic anemia (AIHA) elicited by cold-sensitive antibodies including cold agglutinins. Ninety percent of cold agglutinins belong to the IgM kappa category and bind to red blood cell surface antigens at temperatures of ≤ 37 °C, thus inducing hemolysis [1-3]. CAD accounts for approximately 25 % of AIHA cases, with an incidence and prevalence of 1 case per million persons per year and 16 cases per million persons, respectively [4, 5].

Patient and disease characteristics in a small CAD cohort

Patient and disease characteristics in a small CAD cohort A retrospective analysis hints at the wide range of cold agglutinin disease (CAD) clinical behavior. Koudouna et al. investigated the characteristics of 8 patients with CAD at the time of diagnosis [1]. Median age was 62 years, and 5 patients were women. Hematologic malignancies constituted 50 % of underlying medical conditions; in 37 %, hepatitis B/C was the associated disease, and in 13 %, autoimmune disorders. The median hemoglobin level at presentation was 8.9 g/dL. Slightly elevated serum CRP and ferritin levels represented common findings.

Downloads

All downloads from EHA 2020

Slide Kit CAD / PNH

Full report (english)

EXPERT VIDEOS

All videointerviews from EHA 2020

Shirley D’Sa talks about promising new agents/regimens in the treatment of Waldenström’s macroglobulinemia with respect to efficacy and safety, next-generation BTK inhibitors and recent developments in the management of cold agglutinin disease.

Constantine Tam depicts the most interesting trial results in the field of CLL treatment at the EHA congress and gives an outlook on future treatment options for CLL and mantle cell lymphoma.

Veronique Leblond highlights relevant factors for the selection of treatment in newly diagnosed and relapsed Waldenström’s macroglobulinemia, the connection of BTK inhibitors and MYD88 or CXCR4 mutations and discusses the risk-benefit profile of these drugs.

Peter Hillmen gives an overview of the most relevant treatment strategies in ­patients with paroxysmal nocturnal hemoglobinuria and further explains the advantages of proximal over terminal complement inhibition.